Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin August Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

Excellent Results for Affimer Technology in Industry-Standard Immunogenicity Study Using Human Samples

publication date: May 8, 2017
 | 
author/source: Avacta Life Sciences

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to report that the first major immunogenicity study of Affimer technology using human ex-vivo samples has concluded successfully with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin®.

avactaUnwanted immunogenicity occurs when a patient has an immune response to a drug which can lead to reduced effectiveness of the drug and possibly lead to serious adverse side effects. It is therefore essential that a new drug platform, such as Affimer technology, is shown not to cause a significant intrinsic immunogenic response.

The Company has now completed the first major study of immunogenicity for the Affimer technology using samples from fifty healthy volunteers. Multiple versions of the Affimer technology were tested in the study and benchmarked against the marketed monoclonal antibody Avastin.

All versions of the Affimer scaffold showed a low response in these industry-standard tests comparable to Avastin, confirming that the Affimer technology has no significant immunogenicity.

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “This excellent data significantly de-risks the Affimer technology as a therapeutic platform addressing the multi-billion dollar biotherapeutics market and is a major milestone and value inflection point for the Company.

Immunogenicity is a key concern for any protein-based therapeutic in development, especially for a new therapeutic platform such as that based on our Affimer technology. I am delighted that the results of this extensive study shows unequivocally that none of the Affimer scaffolds induce a significant immunogenic response. This bodes well for their further development as therapeutics, as there is an accepted correlation between this type of ex-vivo study and a patient’s immunogenic response when dosed with the drug in the clinic.

In the past year the Avacta has hit multiple key milestones for the Affimer technology including successful outcomes of the first in vivo pharmacokinetics and efficacy studies and now the successful outcome of a critical immunogenicity trial. Together this significant progress supports both our conversations with potential pharma partners and our objective to take the first Affimer candidate into clinical development in 2019.”


more about avacta


more news from avacta


 


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners